Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis — An Inception Cohort Study

SOFIA AJEGANOVA, ULF de FAIRE, TOMAS JOGESTRAND, JOHAN FROSTEGÅRD and INGIÄLD HAFSTRÖM
The Journal of Rheumatology June 2012, 39 (6) 1146-1154; DOI: https://doi.org/10.3899/jrheum.111334
SOFIA AJEGANOVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sofia.ajeganova{at}karolinska.se
ULF de FAIRE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMAS JOGESTRAND
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHAN FROSTEGÅRD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
INGIÄLD HAFSTRÖM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Kaplan-Meier curves show the CVD event-free survival in 104 RA patients with no history of CVD events, stratified by carotid intima-media thickness (cIMT; upper tertile, ≥ 0.73 mm) in tertiles (A); and by occurrence of bilateral carotid plaque (B). Vertical lines mark survival rates 10 years after onset of RA disease. P values compare between-group difference by log-rank test.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Kaplan-Meier curves show the CVD event-free survival in 104 RA patients with no history of CVD events, stratified by carotid intima-media thickness (cIMT; upper tertile, ≥ 0.73 mm) in tertiles (A); and by occurrence of bilateral carotid plaque (B). Vertical lines mark survival rates 10 years after onset of RA disease. P values compare between-group difference by log-rank test.

  • Predicted means of variables plotted against time by incident CVD events throughout the study in the 105 patients with RA (1 case contributed only up to 12 months of followup before occurrence of a CVD event), analyzed by mixed linear models. A: log oxidized low-density lipoprotein (oxLDL); B: probability of the low tertile of IgM antiphosphorylcholine antibodies (anti-PC); C: Stanford Health Assessment Questionnaire (HAQ); D: VAS for pain. P values compare interaction with time factor.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Predicted means of variables plotted against time by incident CVD events throughout the study in the 105 patients with RA (1 case contributed only up to 12 months of followup before occurrence of a CVD event), analyzed by mixed linear models. A: log oxidized low-density lipoprotein (oxLDL); B: probability of the low tertile of IgM antiphosphorylcholine antibodies (anti-PC); C: Stanford Health Assessment Questionnaire (HAQ); D: VAS for pain. P values compare interaction with time factor.

Tables

  • Figures
    • View popup
    Table 1.

    Characteristics of the 114 patients with rheumatoid arthritis (RA), according to incident cardiovascular disease (CVD) events. Values expressed as mean (SD) or median (IQR).

    Incident CVD Event
    VariablesNever (referent group)After RA OnsetBefore RA Onset
    No. patients88179
    Age at RA onset, yrs48.6 (10.9)55.3 (7.2)*63.9 (7)***
    Men, n (%)25 (28.4)4 (23.5)7 (77.8)**
    CVD risk factors during the study
      Ever-smoking, n (%)60 (68.2)13 (76.5)7 (77.8)
      Hypertension, n (%)48 (54.5)12 (70.6)7 (77.8)
      Diabetes mellitus, n (%)5 (5.7)2 (11.8)1 (11.1)
      Body mass index at 5 yrs, kg/m226 (4.8)24.9 (4.3)23.9 (2.9)
      Hyperlipidemia, n (%)57 (64.8)15 (88.2)*8 (88.9)
    Novel markers at baseline
      oxLDL, U/I53 (44.8–64.9)55.8 (48.9–64.6)41.4 (28.9–64.4)
      IgM anti-PC, U/ml70.6 (33.6–148.6)76.7 (38–141.8)57.3 (47.6–59)
    ΔoxLDL 0–60 mo−9 (−17)−21 (−18.5)*−9.6 (−20)
    Δanti-PC 0–60 mo6.7 (−3.4; 29.5)13.9 (−10; 50.5)3.3 (−0.9; 18.1)
    RA manifestations at baseline
      ESR, mm/h39 (27–56)36 (17–52)35 (29–47)
      CRP, mg/l24 (11–48)22 (6–43)26 (11–42)
      DAS285.5 (1)4.6 (1.3)*5.5 (1)
      HAQ1.2 (0.5)1 (0.8)1 (0.3)
      VAS pain48.7 (20.6)38.2 (29.3)51.6 (16.4)
    RF positivity, n (%)52 (59.1)12 (70.6)3 (33.3)
    ΔESR 0–12 mo26.6 (22)23.5 (18.8)23.8 (18.2)
    ΔCRP 0–12 mo13 (0–34)12 (–2; 31)17 (2–25)
    ΔDAS28 0–12 mo2.4 (1.5)1.5 (1.2)**2.4 (1.2)
    ΔHAQ 0–12 mo0.7 (0.6)0.3 (0.5)*0.5 (0.6)
    ΔVAS pain 0–12 mo25.5 (26.4)5.4 (16.8)*24.9 (37.8)
    HAQ at 5 yrs0.6 (0.5)1.0 (0.8)*0.5 (0.5)
    RA treatment during the study
      Methotrexate, n (%)76 (86.4)11 (64.7)*4 (44.4)**
      Antimalarials, n (%)34 (38.6)9 (52.9)2 (22.2)
      Biologics, n (%)34 (38.6)8 (47.1)2 (22.2)
      Glucocorticoids, n (%)43 (48.9)10 (58.8)6 (66.7)
      NSAID, n (%)56 (63.6)11 (64.7)5 (55.6)
    Carotid ultrasound measurements
      Mean cIMT, mm0.66 (0.59–0.75)0.66 (0.6–0.77)0.77 (0.73–0.99)**
      cIMT, upper tertile†, n (%)26 (29.5)6 (35.3)6 (66.7)*
      Carotid plaque
        None, n (%)30 (34.1)4 (23.5)0
        Unilateral, n (%)31 (35.2)2 (11.8)*1 (11.1)**
        Bilateral, n (%)27 (30.7)11 (64.7)**8 (88.9)*
    • ↵* p < 0.05;

    • ↵** p ≤ 0.01;

    • ↵*** p ≤ 0.001.

    • ↵† cIMT upper tertile ≥ 0.73 mm. CVD: cardiovascular disease; TC: total cholesterol; LDL: low-density lipoprotein; oxLDL: oxidized LDL; anti-PC: anti-phosphorylcholine antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; RF: rheumatoid factor; Δ: reduction between assessments at times as indicated; NSAID: nonsteroidal antiinflammatory drug; cIMT: carotid intima-media thickness.

    • View popup
    Table 2.

    Rates of incident cardiovascular disease (CVD) events (per 100 person-years) in the 104 patients with RA, according to cIMT in tertiles and carotid plaque occurrence on carotid ultrasound at the 5-year assessment.

    Followup Periods and VariablesIncident CVD Events, n (95% CI)Person-yrsRate per 100 Person-yrs (95% CI)
    Whole study period
      cIMT, low tertiles10 (3.8–16.2)8831.13 (0.43–1.83)
      cIMT, upper tertile6 (1.2–10.8)3751.6 (0.32–2.88)
      Plaque none/unilateral6 (1.2–10.8)8400.71 (0.14–1.29)
      Plaques bilateral10 (3.8–16.2)4182.39 (0.91–3.88)
    After ultrasound examination of carotids
      cIMT, low tertiles10 (3.8–16.2)5041.98 (0.75–3.21)
      cIMT, upper tertile6 (1.2–10.8)214.52.8 (0.56–5.03)
      Plaque none/unilateral6 (1.2–10.8)493.51.22 (0.24–2.2)
      Plaques bilateral10 (3.8–16.2)2254.44 (1.69–7.2)
    • cIMT: carotid intima-media thickness.

    • View popup
    Table 3.

    Hazard ratios (HR) for incident cardiovascular disease in the 105 patients with RA (1 case excluded when indicated), univariate and age-adjusted Cox regression analyses.

    VariablesHR (95% CI)pAge-adjusted HR (95% CI)p
    Age at RA onset1.06 (1.01–1.11)0.016–
    ΔoxLDL (60–0 mo)†1.03 (1.01–1.06)0.0081.03 (1.0–1.06)0.035
    ΔDAS28 (0–12 mo)0.69 (0.49–0.98)0.0410.68 (0.5–0.97)0.035
    ΔHAQ (0–12 mo)0.36 (0.15–0.86)0.0200.35 (0.15–0.82)0.016
    ΔHAQ (0–60 mo)†0.29 (0.15–0.58)0.0000.26 (0.13–0.55)0.000
    ΔVAS pain (0–12 mo)0.97 (0.95–0.99)0.0040.97 (0.95–0.99)0.005
    HAQ at 5 yrs†2.53 (1.31–4.87)0.0062.54 (1.31–4.92)0.006
    MTX use0.32 (0.12–0.87)0.0250.34 (0.12–0.91)0.033
    Bilateral carotid plaque†3.34 (1.21–9.22)0.0202.16 (0.66–7.05)0.20
    • ↵† Analyses where 1 case was excluded due to CVD occurrence about 2 years after disease onset. oxLDL: oxidized low-density lipoprotein; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; MTX: methotrexate; cIMT: carotid intima-media thickness.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 6
1 Jun 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis — An Inception Cohort Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis — An Inception Cohort Study
SOFIA AJEGANOVA, ULF de FAIRE, TOMAS JOGESTRAND, JOHAN FROSTEGÅRD, INGIÄLD HAFSTRÖM
The Journal of Rheumatology Jun 2012, 39 (6) 1146-1154; DOI: 10.3899/jrheum.111334

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis — An Inception Cohort Study
SOFIA AJEGANOVA, ULF de FAIRE, TOMAS JOGESTRAND, JOHAN FROSTEGÅRD, INGIÄLD HAFSTRÖM
The Journal of Rheumatology Jun 2012, 39 (6) 1146-1154; DOI: 10.3899/jrheum.111334
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Validation of Handheld Ultrasound Devices for Point-of-Care Use in Rheumatology: Focus on Synovitis, Doppler Activity, Erosions, and Tendon Lesions
  • Persistent Opioid Exposure in Older Adults With Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing
  • What Makes Axial Spondyloarthritis Difficult to Manage? A Qualitative Study of Patient and Rheumatologist Perspectives
Show more Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire